IPP Bureau
Shilpa Biologicals partners with mAbTree Biologics AG for a novel immunooncology asset
By IPP Bureau - March 18, 2025
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Lupin receives tentative approval from USFDA for Amifampridine Tablets
By IPP Bureau - March 18, 2025
Amifampridine Tablets, 10 mg are indicated for the treatment of Lambert-Eaton myasthenic syndrome in adults and pediatric patients 6 years of age and older.
Morepen launches Empamore for diabetes care with affordable treatment
By IPP Bureau - March 18, 2025
Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health
Dr. Reddy's issues nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL in US
By IPP Bureau - March 18, 2025
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
CKD cases surge to 16.38% in Indians aged 15+
By IPP Bureau - March 17, 2025
Experts urge early detection & better access to care
Strides Pharma global to acquire 100% stake in Amextel
By IPP Bureau - March 17, 2025
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
Zydus receives final approval from USFDA for Eluxadoline Tablets, 75 mg and 100 mg
By IPP Bureau - March 17, 2025
Eluxadoline is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhoea
Azelis signs distribution agreement with Evonik to expands pharmaceutical offering in Malaysia and Singapore
By IPP Bureau - March 13, 2025
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
OneSource Specialty Pharma strengthens its board by appointing new directors
By IPP Bureau - March 13, 2025
These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance
Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India
By IPP Bureau - March 13, 2025
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Alkem launches generic empagliflozin and its combinations in India under ‘Empanorm’
By IPP Bureau - March 13, 2025
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
Zydus receives final approval from USFDA for Methenamine Hippurate Tablets USP, 1 gram
By IPP Bureau - March 13, 2025
Methenamine Hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections
Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
By IPP Bureau - March 13, 2025
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Sigachi Industries signs MoU with INS Kalinga to promote healthy living
By IPP Bureau - March 13, 2025
The programme will take place on the 2nd Sunday of every month
Poly Medicure receives MDR certification for 54 products
By IPP Bureau - March 12, 2025
The MDR certification reafirms that these products meet the highest safety, quality, and regulatory standards
